MaxCyteMXCT
MXCT
About: MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Employees: 114
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
9% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 43
1.98% less ownership
Funds ownership: 68.83% [Q4 2024] → 66.85% (-1.98%) [Q1 2025]
4% less funds holding
Funds holding: 119 [Q4 2024] → 114 (-5) [Q1 2025]
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
36% less capital invested
Capital invested by funds: $303M [Q4 2024] → $194M (-$109M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for MXCT.
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
Neutral
Seeking Alpha
1 month ago
MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Eric Abdel - IR Maher Masoud - President and CEO Doug Swirsky - CFO Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Mark Massaro - BTIG Chad Wiatrowski - TD Cowen Dan Arias - Stifel Operator Good day and thank you for standing by. Welcome to the MaxCyte First Quarter Earnings Conference Call.
Neutral
Zacks Investment Research
1 month ago
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance.
Neutral
GlobeNewsWire
2 months ago
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
2 months ago
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
2 months ago
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
2 months ago
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
3 months ago
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price
MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations.
Neutral
Seeking Alpha
3 months ago
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:12 PM ET MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2024 Earnings Conference Call March 11, 2025, 16:30 PM ET Company Participants Maher Masoud - President and CEO Doug Swirsky - CFO Erik Abdo - IR Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Brendan Smith - TD Cowen Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by and welcome to MaxCyte's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
Charts implemented using Lightweight Charts™